#15#
Revisiones (todas) *** Reviews (all)
RESPIRATORY TRACT TUMORS
(Conceptos / Keywords: NSCLC; SCLC, Mesotheliomas; Tracheal tumors; Bronchial tumors; etc).
February - March 2013
El sistema de alerta de literatura biomédica© es un servicio GRATUITO. La literatura ha sido compuesta en base a una patente que permite la indexización y ordenación de los artículos por orden de importancia. Consecuentemente existe un copyright de carácter compilativo (todos los derechos reservados). Este documento sólo contiene artículos escritos en Castellano y/o Inglés. Para mayor información visite el portal de la compañía haciendo un clic en la palabra Enlace/Link
The biomedical literature© alert system is a FREE service. The literature has been arranged according to a patent, which entitles the right to cataloguing and sorting articles by true relevance. Consequently, a compilation copyright exists (all rights reserved). Only articles written in Spanish and/or English are included. For more information please visit the website of the company by clicking on the following Enlace/Link
----------------------------------------------------
[1]
TÍTULO / TITLE: - Computed tomography screening for lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - JAMA. 2013 Mar 20;309(11):1163-70. doi: 10.1001/jama.2012.216988.
●● Enlace al texto completo (gratuito o de pago) 1001/jama.2012.216988
AUTORES / AUTHORS: - Boiselle PM
INSTITUCIÓN / INSTITUTION: - Harvard Medical School, and, Center for Airway Imaging, Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.pboisell@bidmc.harvard.edu
RESUMEN / SUMMARY: - IMPORTANCE: Low-dose computed tomography (CT) screening was shown to reduce lung cancer-specific mortality in a large randomized trial of a high-risk population. The decision to pursue CT screening for lung cancer is a timely question raised by individuals at risk of lung cancer and by their health care practitioners. OBJECTIVES: To discuss the evidence for use of chest x-rays and low-dose CT in screening for lung cancer; to describe potential benefits, harms, and uncertainties of CT screening; and to review current guidelines for CT screening. EVIDENCE REVIEW: MEDLINE and the Cochrane Library were searched from 1984 to 2012. Additional citations were obtained from lists of references from select research and review articles on this topic. Evidence was graded using the American Hospital Association level of evidence guidelines. FINDINGS: Low-dose CT screening has been associated with a 20% reduction in lung cancer mortality in a large randomized controlled trial (National Lung Screening Trial [NLST]) of a high-risk population. Mortality data have not yet been reported for 5 other randomized controlled trials, and the sample sizes were too small to detect a meaningful difference in 2 other completed trials. A major risk of CT screening is a high false-positive rate, with associated risks and costs associated with follow-up CT scans and the potential for more invasive diagnostic procedures. Published guidelines for screening indicate a consensus that screening may be indicated for individuals who meet entry criteria for the NLST, but some guidelines expand their recommendations for screening beyond these criteria. CONCLUSIONS AND RELEVANCE: Individuals at high risk of lung cancer who meet the criteria for CT screening in published guidelines should participate in an informed and shared decision-making process by discussing the potential benefits, harms, and uncertainties of screening with their physicians.
----------------------------------------------------
[2]
TÍTULO / TITLE: - Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - BMJ. 2013 Feb 7;346:f165. doi: 10.1136/bmj.f165.
AUTORES / AUTHORS: - Heikkila K; Nyberg ST; Theorell T; Fransson EI; Alfredsson L; Bjorner JB; Bonenfant S; Borritz M; Bouillon K; Burr H; Dragano N; Geuskens GA; Goldberg M; Hamer M; Hooftman WE; Houtman IL; Joensuu M; Knutsson A; Koskenvuo M; Koskinen A; Kouvonen A; Madsen IE; Magnusson Hanson LL; Marmot MG; Nielsen ML; Nordin M; Oksanen T; Pentti J; Salo P; Rugulies R; Steptoe A; Suominen S; Vahtera J; Virtanen M; Vaananen A; Westerholm P; Westerlund H; Zins M; Ferrie JE; Singh-Manoux A; Batty GD; Kivimaki M
INSTITUCIÓN / INSTITUTION: - Finnish Institute of Occupational Health, 00250 Helsinki, Finland. katriina.heikkila@ttl.fi
RESUMEN / SUMMARY: - OBJECTIVE: To investigate whether work related stress, measured and defined as job strain, is associated with the overall risk of cancer and the risk of colorectal, lung, breast, or prostate cancers. DESIGN: Meta-analysis of pooled prospective individual participant data from 12 European cohort studies including 116,056 men and women aged 17-70 who were free from cancer at study baseline and were followed-up for a median of 12 years. Work stress was measured and defined as job strain, which was self reported at baseline. Incident cancers (all n=5765, colorectal cancer n=522, lung cancer n=374, breast cancer n=1010, prostate cancer n=865) were ascertained from cancer, hospital admission, and death registers. Data were analysed in each study with Cox regression and the study specific estimates pooled in meta-analyses. Models were adjusted for age, sex, socioeconomic position, body mass index (BMI), smoking, and alcohol intake RESULTS: A harmonised measure of work stress, high job strain, was not associated with overall risk of cancer (hazard ratio 0.97, 95% confidence interval 0.90 to 1.04) in the multivariable adjusted analyses. Similarly, no association was observed between job strain and the risk of colorectal (1.16, 0.90 to 1.48), lung (1.17, 0.88 to 1.54), breast (0.97, 0.82 to 1.14), or prostate (0.86, 0.68 to 1.09) cancers. There was no clear evidence for an association between the categories of job strain and the risk of cancer. CONCLUSIONS: These findings suggest that work related stress, measured and defined as job strain, at baseline is unlikely to be an important risk factor for colorectal, lung, breast, or prostate cancers.
----------------------------------------------------
[3]
TÍTULO / TITLE: - Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Exp Clin Cancer Res. 2013 Mar 15;32:15. doi: 10.1186/1756-9966-32-15.
●● Enlace al texto completo (gratuito o de pago) 1186/1756-9966-32-15
AUTORES / AUTHORS: - Yang Y; Xie Y; Xian L
INSTITUCIÓN / INSTITUTION: - Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, China. Xianlei59@163.com.
RESUMEN / SUMMARY: - The recent studies have evaluated the relationship between BRCA1 expression and clinical outcome of chemotherapy (mainly focused on platinum-based and toxal-based treatment) in NSCLC patients, but the results were inconclusive and controversial. Our aim of this study was to evaluate this association by literature based system review and meta-analysis.PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases were used to retrieve the relevant articles. The interested outcome included objective response rate (ORR), overall survival (OS) and event-free survival (EFS). The pooled odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) ware estimated.After specific inclusion and exclusion criteria, 23 studies fulfilled the criteria and were included in our analysis. In 17 platinum-based studies, low/negative BRCA1 was in favor of better ORR (OR = 1.70, 95%CI = 1.32-2.18), longer OS and EFS (HR = 1.58, 95%CI = 1.27-1.97, and HR = 1.60, 95%CI = 1.07-2.39 for OS and EFS, respectively). In 4 toxal-based chemotherapy studies, the patients with high/positive BRCA1 had better ORR (OR = 0.41, 95%CI = 0.26-0.64), OS and EFS were not evaluated as the insufficient data available.Overall, BRCA1 might be a useful biomarker to predict clinical outcome for personal chemotherapy in NSCLC patients in the future.
----------------------------------------------------
[4]
TÍTULO / TITLE: - A modified exercise protocol may promote continuance of exercise after the intervention in lung cancer patients-a pragmatic uncontrolled trial.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Support Care Cancer. 2013 Mar 20.
●● Enlace al texto completo (gratuito o de pago) 1007/s00520-013-1781-z
AUTORES / AUTHORS: - Andersen AH; Vinther A; Poulsen LL; Mellemgaard A
INSTITUCIÓN / INSTITUTION: - Department of Physical Therapy, Dept. O, Herlev University Hospital, Herlev Ringvej 75, DK-2730, Herlev, Denmark, Andreas.Holst.Andersen@regionh.dk.
RESUMEN / SUMMARY: - PURPOSE: A previous study investigated the effects of a well-documented COPD exercise protocol in lung cancer patients. The study showed improvements in physical fitness, but poor adherence to continued exercise after intervention. The aim of the present study was to investigate the effect of a modified exercise intervention on post-intervention adherence, and physical fitness in a broad group of lung cancer patients. METHODS: Fifty-nine patients enrolled in a 9-week exercise program. Eligibility criteria were limited to presence of motivation, and absence of comorbidities that could jeopardize safety. The intervention included three times 3 weeks of exercise (3 weeks supervised, 3 weeks home-based and 3 weeks supervised). The patient’s activities were structured by logbooks during the 3 weeks at home. VO2 max was estimated at baseline and at the end of intervention. Self-reported quality of life was recorded before and after the exercise program. Post-intervention exercise activity was assessed by telephone interviews 4 weeks after intervention. RESULTS: Fifty-one patients initiated the exercise intervention and 29 patients successfully completed the exercise program. Full data were available for 25 patients regarding estimated VO2 max. Twenty-six of the 29 were available for follow-up with respect to continuance of physical activity. Among the 26 who completed the 9-week training program, 18 (69 %) continued to be physically active on a daily basis. No change in estimated VO2 max was observed. A trend towards increased quality of life and better symptom control was noted. CONCLUSIONS: The present study showed an increased level of continuance of physical activity compared to the previous study. The present study could, however, not repeat the significant improvements in estimated VO2 max from the previous study.
----------------------------------------------------
[5]
TÍTULO / TITLE: - Long-term survival in video-assisted thoracoscopic lobectomy vs open lobectomy in lung-cancer patients: a meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Eur J Cardiothorac Surg. 2013 Feb 14.
●● Enlace al texto completo (gratuito o de pago) 1093/ejcts/ezt051
AUTORES / AUTHORS: - Taioli E; Lee DS; Lesser M; Flores R
INSTITUCIÓN / INSTITUTION: - Division of Thoracic Surgery, Mount Sinai School of Medicine, New York, NY, USA.
RESUMEN / SUMMARY: - Video-assisted thoracic surgery (VATS) lobectomy is an appealing alternative to open lobectomy via thoracotomy for non-small-cell lung cancer. However, there is no clear consensus in regard to the superior approach for long-term outcomes. The data are limited to small series, which precludes further clarification. Meta-analysis of these studies was performed in order to obtain a more objective determination of the oncological feasibility of VATS lobectomy. A systematic review of the PubMed and Embase databases was performed. Twenty observational studies reporting long-term outcomes were included, involving 2106 VATS and 2661 thoracotomy patients. There was an advantage in long-term mortality for patients who underwent VATS vs patients who underwent thoracotomy (meta difference in survival: 5%; 95% CI: 3-6%) with large heterogeneity among studies (Q = 42.6; P-value: 0.001; I(2) = 55.7%). There was no evidence of publication bias. Compared with open lobectomy, VATS lobectomy appears to have improved long-term outcomes.
----------------------------------------------------
[6]
TÍTULO / TITLE: - Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Clin Oncol. 2013 Mar 10;31(8):1039-49. doi: 10.1200/JCO.2012.45.3753. Epub 2013 Feb 11.
●● Enlace al texto completo (gratuito o de pago) 1200/JCO.2012.45.3753
AUTORES / AUTHORS: - Li T; Kung HJ; Mack PC; Gandara DR
INSTITUCIÓN / INSTITUTION: - University of California Davis Comprehensive Cancer Center, Division of Hematology and Oncology, 4501 X St, Ste 3016, Sacramento, CA 95817; tianhong.li@ucdmc.ucdavis.edu.
RESUMEN / SUMMARY: - Substantial advances have been made in understanding critical molecular and cellular mechanisms driving tumor initiation, maintenance, and progression in non-small-cell lung cancer (NSCLC). Over the last decade, these findings have led to the discovery of a variety of novel drug targets and the development of new treatment strategies. Already, the standard of care for patients with advanced-stage NSCLC is shifting from selecting therapy empirically based on a patient’s clinicopathologic features to using biomarker-driven treatment algorithms based on the molecular profile of a patient’s tumor. This approach is currently best exemplified by treating patients with NSCLC with first-line tyrosine kinase inhibitors when their cancers harbor gain-of-function hotspot mutations in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangements. These genotype-based targeted therapies represent the first step toward personalizing NSCLC therapy. Recent technology advances in multiplex genotyping and high-throughput genomic profiling by next-generation sequencing technologies now offer the possibility of rapidly and comprehensively interrogating the cancer genome of individual patients from small tumor biopsies. This advance provides the basis for categorizing molecular-defined subsets of patients with NSCLC in whom a growing list of novel molecularly targeted therapeutics are clinically evaluable and additional novel drug targets can be discovered. Increasingly, practicing oncologists are facing the challenge of determining how to select, interpret, and apply these new genetic and genomic assays. This review summarizes the evolution, early success, current status, challenges, and opportunities for clinical application of genotyping and genomic tests in therapeutic decision making for NSCLC.
----------------------------------------------------
[7]
TÍTULO / TITLE: - Radiofrequency ablation for non-small-cell lung cancer in a single-lung patient: Case report and review of the literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Lung Cancer. 2013 Mar 5. pii: S0169-5002(13)00062-7. doi: 10.1016/j.lungcan.2013.02.003.
●● Enlace al texto completo (gratuito o de pago) 1016/j.lungcan.2013.02.003
AUTORES / AUTHORS: - Modesto A; Giron J; Massabeau C; Sans N; Berjaud J; Mazieres J
INSTITUCIÓN / INSTITUTION: - Radiation Oncology Department, Institut Claudius Regaud, 20-24 rue du Pont Saint Pierre, 31000 Toulouse, France. Electronic address: Anouchka.modesto@gmail.com.
RESUMEN / SUMMARY: - BACKGROUND: Radiofrequency thermal ablation is an alternative option to manage primary or metastatic lung malignancies. It is particular useful for unresectable lesions because of the disease’s location, prior resection, or comorbidities. Patients presenting with a lung tumor that occurs in a single lung due to a prior pneumonectomy are difficult to manage with a curative intent due to the risk of complications after local treatment. MATERIALS AND METHODS: We hereby report on treatment of a primary non-small-cell lung cancer in a previously contralateral pneumonectomised patient using per-cutaneous pulmonary radiofrequency thermal ablation. We also discuss literature that describes similar alternative minimally invasive procedures. CONCLUSION: Despite being a high-risk procedure, radiofrequency should be considered for patients with a single lung particularly when ineligible to surgery or stereotactic ablative radiation therapy. The procedure should be ideally associated with a pre-operative preventive chest tube.
----------------------------------------------------
[8]
TÍTULO / TITLE: - Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Eur J Cardiothorac Surg. 2013 Jan 30.
●● Enlace al texto completo (gratuito o de pago) 1093/ejcts/ezt015
AUTORES / AUTHORS: - Zhang Z; Zhang Y; Feng H; Yao Z; Teng J; Wei D; Liu D
INSTITUCIÓN / INSTITUTION: - Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
RESUMEN / SUMMARY: - The study aimed to compare the reported oncological outcomes based on satisfactory lymph node dissection (LND) or lymph node sampling (LNS), systemic and loco-regional recurrence rate and long-term survival rate of patients with early-stage non-small-cell lung cancer (NSCLC) who underwent video-assisted thoracic surgery (VATS) lobectomy or thoracotomy lobectomy. A systematic review was conducted using PubMed, EMBASE and OVID-EBMR databases ranging from 1990 to 2011. The studies compared VATS and thoracotomy for patients with NSCLC, with results including LND or LNS where recurrence as well as survival rates were identified. Data were abstracted by two reviewers independently. Mean difference or risk ratio (RR) were pooled using RevMan 5.0 statistical software. 5389 cases were included, of which 2380 underwent VATS and 3009 underwent thoracotomy. There was no significant difference in the number of total LND or LNS procedures (MD: -0.63; 95% confidence intervals (95% CI): -1.47 to 0.21; P = 0.14) or mediastinal LND or LNS (MD: -0.51; 95% CI: -1.58 to 0.56; P = 0.35) between the two groups. Systemic (RR: 0.61; 95% CI: 0.48 to 0.78; P < 0.01) and loco-regional (RR: 0.66; 95% CI: 0.46 to 0.95; P = 0.03) recurrence rates were significantly lower in the VATS group. Moreover, a significantly higher survival rate (RR: 1.09; 95% CI: 1.03 to 1.15; P < 0.01) was also demonstrated by a Forest plot in the VATS group. These results suggest that VATS lobectomy might be an eligible alternative in place of thoracotomy in patients with early-stage NSCLC by reducing recurrence and improving survival rates.
----------------------------------------------------
[9]
TÍTULO / TITLE: - Lack of association between XRCC3 rs861539 (C > T) polymorphism and lung cancer risks: an update meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Tumour Biol. 2013 Mar 26.
●● Enlace al texto completo (gratuito o de pago) 1007/s13277-013-0722-2
AUTORES / AUTHORS: - Shi CL; Li R; Xiong LW; Gu AQ; Han BH; Gu W
INSTITUCIÓN / INSTITUTION: - Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, 241 West Huaihai Rd, Shanghai, 200030, China.
RESUMEN / SUMMARY: - X-ray repair cross-complementing protein 3 (XRCC3) belongs to DNA double-strand break repair pathway and XRCC3 rs861539 (C > T) polymorphism has been suspected with lung cancer risk. However, results from previous studies are inconclusive and affected by bias. Electronic databases of PubMed, EMBASE, China National Knowledge Infrastructure, and SinoMed were searched. References of relative reviews were also screened. Pooled odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated to estimate the association strength. A number of 18 eligible studies with 6 studies of Asians, 11 of Caucasians, and 1 of African were extracted and analyzed, including 4,896 lung cancer cases and 6,360 controls. No significant correlation between XRCC3 polymorphism and lung cancer risk was observed in homozygote comparison (CC vs. TT; OR = 0.877; 95 % CI, 0.659, 1.168), heterozygote comparison (CT vs. TT; OR = 0.857; 95 % CI, 0.675, 1.089), dominant model (CC/CT vs. TT; OR = 0.862; 95 % CI, 0.663, 1.123), or recessive model (CC vs. CT/TT; OR = 1.047; 95 % CI, 0.956, 1.145). Subgroup analyses of ethnicity and controls did not reveal any significant association with lung cancer risk. No publication bias was detected. In this update meta-analysis of 18 studies and 11,256 participants, we find that XRCC3 rs861539 polymorphism does not contribute to lung cancer risk and there is no difference between Asians and Caucasians.
----------------------------------------------------
[10]
TÍTULO / TITLE: - Current status and future strategies for multimodality treatment of unresectable stage III non-small-cell lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Eur Respir J. 2013 Feb 21.
●● Enlace al texto completo (gratuito o de pago) 1183/09031936.00143112
AUTORES / AUTHORS: - Huber RM; Reck M; Thomas M
INSTITUCIÓN / INSTITUTION: - University of Munich - Campus Innenstadt, and Thoracic Oncology Centre Munich, Germany.
RESUMEN / SUMMARY: - Stage III non-small cell lung cancer (NSCLC) encompasses a heterogeneous group of patients, some of whom may be candidates for potentially curative surgery, although for the majority surgery is not an option. Recommended therapy for patients with unresectable stage III disease is concurrent treatment with chemotherapy and thoracic radiotherapy, although even with this dual modality therapy survival remains disappointing. Novel classes of agents including targeted therapies have been shown to improve survival in advanced stage NSCLC, raising the possibility that these agents may have benefits in multimodal therapy when combined with chemoradiotherapy. Here we consider the rationale for combining new agents with chemoradiotherapy and the evidence from clinical studies assessing multimodal strategies for the management of patients with unresectable stage III NSCLC.
----------------------------------------------------
[11]
TÍTULO / TITLE: - Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Thorac Oncol. 2013 Mar;8(3):352-8. doi: 10.1097/JTO.0b013e31827d5280.
●● Enlace al texto completo (gratuito o de pago) 1097/JTO.0b013e31827d5280
AUTORES / AUTHORS: - Marchetti A; Ardizzoni A; Papotti M; Crino L; Rossi G; Gridelli C; Barberis M; Maiorano E; Normanno N; Taddei GL; Scagliotti G; Clemente C; Pinto C
INSTITUCIÓN / INSTITUTION: - Center of Predictive Molecular Medicine, Center of Excellence on Aging, University-Foundation, Chieti, Italy. amarchetti@unich.it
RESUMEN / SUMMARY: - INTRODUCTION: Recent clinical trials led to the approval of crizotinib (PF-02341066; Pfizer) by the U.S. Food and Drug Administration for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumors are positive for anaplastic lymphoma kinase (ALK) alterations. The European Medicines Agency accepted the regulatory submission of crizotinib for the treatment of these patients. Therefore, ALK gene testing has become mandatory to choose the most appropriate therapy. METHODS: To help physicians, involved in the management of NSCLC patients to be treated with ALK inhibitors in Italy, the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology identified a large panel of Italian medical oncologists and pathologists that outlined recommendations for ALK testing in NSCLC patients. RESULTS: The guidelines produced include specific information on the target patient population, the biological material for molecular analysis, a section dedicated to the histocytopathologic diagnosis of NSCLC, and the methods for the assessment of ALK alterations that are summarized in this article. CONCLUSIONS: Clinicopathologic recommendations were produced to guide the management of NSCLC patients who need to be tested for ALK rearrangements before treatment with ALK inhibitors.
----------------------------------------------------
[12]
TÍTULO / TITLE: - Detection of lung cancer using multiple genetic markers-a systematic review.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Diagn Cytopathol. 2013 Mar 20. doi: 10.1002/dc.22978.
●● Enlace al texto completo (gratuito o de pago) 1002/dc.22978
AUTORES / AUTHORS: - Quintans JS; Antoniolli AR; Onofre FM; Onofre AS
INSTITUCIÓN / INSTITUTION: - Department of Physiology, Federal University of Sergipe, Sao Cristovao, SE, Brazil.
RESUMEN / SUMMARY: - Lung cancer is the leading cause of cancer deaths worldwide, and has one of the lowest survival rates of any solid tumor. In recent years, several attempts have been conducted to improve an early or accelerated diagnosis due to better overall prognosis after therapy. The aim of this study was evaluating the use of genetic markers for diagnosis of lung cancer. This study was conducted in accordance to Transparent Reporting of Systematic Reviews and Meta-Analyses. Three Internet sources were used to search: MEDLINE-PubMed, EMBASE, and LILACS. The databases were searched for studies conducted in the period up to and including May 10, 2011. The following inclusion criteria were applied: lung cancer studies, and the use of genetic markers for diagnosis. Studies using animal models, review articles, meta-analyses, abstracts, conference proceedings, editorials/letters, case reports, incorrect study population, inadequate data, and cytology was not obtained, were excluded. A total of 1,901 abstracts/citations were identified for preliminary review. From 24 final selected studies, 17 referred to chromosomal markers diagnosis, eight to genes as marker, and one to both subjects. Fluorescence in situ hybridization (FISH) was applied in all studies. Despite the limitations of this study, application of genetic markers to lung cancer diagnosis seems to have prognosis value irrespective of detection methodology used. FISH was the main technique applied to diagnose genetics alterations and revealed a high specificity, although some authors reported low sensitivity. Diagn. Cytopathol. 2013. © 2013 Wiley Periodicals, Inc.
----------------------------------------------------
[13]
TÍTULO / TITLE: - Systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Int J Pediatr Otorhinolaryngol. 2013 Mar;77(3):323-8. doi: 10.1016/j.ijporl.2012.12.027. Epub 2013 Jan 29.
●● Enlace al texto completo (gratuito o de pago) 1016/j.ijporl.2012.12.027
AUTORES / AUTHORS: - Clamp PJ; Saunders MW
INSTITUCIÓN / INSTITUTION: - Department of Ear, Nose and Throat Surgery, Bristol Royal Hospital for Children, United Kingdom. philip.clamp@nhs.net
RESUMEN / SUMMARY: - OBJECTIVE: Surgical management of recurrent respiratory papillomatosis (RRP) usually involves resection via microlaryngoscopy. Intralesional injection of cidofovir has been shown to be an effective adjuvant treatment, but remains unlicensed. United Kingdom General Medical Council guidelines recommend the prescribing doctor should “be satisfied that there is a sufficient evidence base and/or experience of using the medicine to demonstrate its safety and efficacy”. This study reviews the published dosing regimens of intralesional cidofovir in the treatment of RRP in order to provide a precedent for those that wish to prescribe it. METHODS: A systematic review of the literature was undertaken using Medline, EMBASE and CINAHL. Articles describing the use of intralesional cidofovir for RRP were reviewed. Information regarding cidofovir concentration, volume, total dose, number of treatments, interval between treatments, overall treatment period and follow up was extracted. RESULTS: Fifty-one articles were identified. Concentration of cidofovir injected ranged from 0.0001mg/ml to 37.5mg/ml, with 5 to 7.5mg/ml being the most common. The volume of cidofovir solution injection ranged from 0.1 to 20ml. The total dose per injection ranged from 0.15 to 105mg. There was wide variation in dosing regimens with different intervals between endoscopies, number of injections and total doses delivered. CONCLUSIONS: Based on this published literature, the precedent for prescribing intralesional cidofovir supports a concentration of 5 to 7.5mg/ml. Volumes up to 5ml per injection are routinely used. Total dose and frequency of cidofovir administration is highly variable. The need for repeat doses of cidofovir should be judged on an individual basis.
----------------------------------------------------
[14]
TÍTULO / TITLE: - Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Radiother Oncol. 2013 Feb 22. pii: S0167-8140(13)00008-X. doi: 10.1016/j.radonc.2013.01.004.
●● Enlace al texto completo (gratuito o de pago) 1016/j.radonc.2013.01.004
AUTORES / AUTHORS: - Senthi S; Haasbeek CJ; Slotman BJ; Senan S
INSTITUCIÓN / INSTITUTION: - Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: s.senthi@vumc.nl.
RESUMEN / SUMMARY: - BACKGROUND AND PURPOSE: Stereotactic ablative radiotherapy (SABR) has improved the survival for medically inoperable patients with peripheral early-stage non-small cell lung cancer (NSCLC). We performed a systematic review of outcomes for central lung tumours. MATERIAL AND METHODS: The systematic review was performed following PRISMA guidelines. Survival outcomes were evaluated for central early-stage NSCLC. Local control and toxicity outcomes were evaluated for any centrally-located lung tumour. RESULTS: Twenty publications met the inclusion criteria, reporting outcomes for 563 central lung tumours, including 315 patients with early-stage NSCLC. There was heterogeneity in the planning, prescribing and delivery of SABR and the common toxicity criteria used to define toxicities (versions 2.0-4.0). Tumour location (central versus peripheral) did not impact overall survival. Local control rates were 85% when the prescribed biologically equivalent tumour dose was 100Gy. Treatment-related mortality was 2.7% overall, and 1.0% when the biologically equivalent normal tissue dose was 210Gy. Grade 3 or 4 toxicities may be more common following SABR for central tumours, but occurred in less than 9% of patients. CONCLUSIONS: Post-SABR survival for early-stage NSCLC is not affected by tumour location. SABR achieves high local control with limited toxicity when appropriate fractionation schedules are used for central tumours.
----------------------------------------------------
[15]
TÍTULO / TITLE: - Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: A meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Eur J Cancer. 2013 Mar 4. pii: S0959-8049(13)00116-0. doi: 10.1016/j.ejca.2013.02.008.
●● Enlace al texto completo (gratuito o de pago) 1016/j.ejca.2013.02.008
AUTORES / AUTHORS: - Zhang R; Ying K; Shi L; Zhang L; Zhou L
INSTITUCIÓN / INSTITUTION: - Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
RESUMEN / SUMMARY: - STUDY OBJECTIVES: This systematic review and meta-analysis was conducted to evaluate the accuracy of the combined endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) techniques and clarify its current role for the mediastinal lymph node staging of lung cancer. METHODS: Medline, Web of Science, Elsevier and Ovid were searched to identify suitable studies up to 15th July 2012. Two investigators independently reviewed articles and extracted data. All EBUS-TBNA plus EUS-FNA studies for the mediastinal node staging of lung cancer were systematically reviewed. Sensitivity, specificity and other accuracy measures were pooled using random-effect models. Summary receiver operating characteristic curves were used to summarise overall test performance. RESULTS: Eight studies met our inclusion criteria. The estimated summary measures for quantitative analysis of EBUS-TBNA plus EUS-FNA for mediastinal nodal staging of lung cancer were sensitivity, 0.86 (95% confidence interval [CI], 0.82-0.90); specificity, 1.00 (95% CI, 0.99-1.00); positive likelihood ratio, 51.77 (95% CI, 22.53-118.94); negative likelihood ratio, 0.15 (95% CI, 0.09-0.25); diagnostic odds ratio, 416.83 (95% CI, 140.08-1240.31); and area under the curve (AUC), 0.99. CONCLUSIONS: The current evidence suggests that the combined technique is more sensitive than EBUS-TBNA or EUS-FNA alone. The diagnostic power of this combined technique is accurate. As an almost completely minimally-invasive examination, EUS-FNA plus EBUS-TBNA may replace more invasive methods for evaluating mediastinal node staging of lung cancer.
----------------------------------------------------
[16]
TÍTULO / TITLE: - Neuroendocrine tumors of larynx—two case reports and literature review.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Coll Antropol. 2012 Nov;36 Suppl 2:173-8.
AUTORES / AUTHORS: - Caric T; Bilic M; Bilic LK; Prgomet D; Kovacic J; Grahovac IT; Hutinec Z
INSTITUCIÓN / INSTITUTION: - University of Zagreb, Dubrava University Hospital, Department of ENT, Head and Neck Surgery, Zagreb, Croatia. tcaric@gmail.com
RESUMEN / SUMMARY: - Neuroendocrine tumors (NET) of the larynx are rare and heterogenous group, with much confusion about nature and classification of these neoplasms in the past. Diagnosis is based primarily on light microscopy and confirmed by immunohistochemistry and electron microscopy. A classification in 4 different types; paraganglioma, typical carcinoid, atypical carcinoid and small cell neuroendocrine carcinoma (SCNC) is a current consensus. Thorough diagnostic and a proper classification of neuroendocrine neoplasms are of paramount importance—prognosis and treatment differ significantly. We present two cases: 63-year old patient with SCNC of the larynx and a 53-year old patient with atypical carcinoid of the larynx. OctreoScan is useful tools for diagnostics and follow up of the patients and it is predictive for effectiveness of octreotide therapy.
----------------------------------------------------
[17]
TÍTULO / TITLE: - The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Curr Med Res Opin. 2013 Mar 21.
●● Enlace al texto completo (gratuito o de pago) 1185/03007995.2013.782282
AUTORES / AUTHORS: - Akerley WL; Nelson RE; Cowie RH; Spinella DG; Hornberger J
INSTITUCIÓN / INSTITUTION: - Huntsman Comprehensive Cancer Center , Salt Lake City, UT , USA.
RESUMEN / SUMMARY: - Abstract Objective: To assess the impact of a serum-based proteomic test for non-small-cell lung cancer (NSCLC) on physician treatment recommendations. Research design and methods: A multivariate, serum-based proteomic test (VeriStrat * ) is commercially available to assist physicians when determining treatment using epidermal growth factor receptor inhibitor (EGFRi) therapy, such as erlotinib (Tarceva dagger ), by stratifying patients into two categories: those with significantly better (‘good’) and those with significantly worse (‘poor’) outcomes following treatment with EGFRi therapy. All tests ordered from August 9, 2011 to November 26, 2012, were considered for this study. Pre- and post-test treatment recommendations were prospectively collected from ordering physicians on a voluntary basis. Only those tests that had both pre- and post-test treatment information were included in the analysis group. Main outcome measures: Proportional change and correlation of treatment recommendations before and after receipt of the test results. Results: Over the duration of the study, 724 physicians ordered 2854 tests. The analysis group comprised the 226 physicians who provided pre- and post-test treatment information (n = 403 tests). Following receipt of the test results, 90.3% (95% CI: 86.4-93.3%) of patients who tested as ‘good’ received erlotinib recommendations versus 9.6% (95% CI: 4.5-17.4%, p < 0.0001) of patients who tested as ‘poor’. Ninety percent of post-test treatment recommendations positively correlated with test results, with 40% showing a change from pre-test considerations. Study limitations: Data based on physicians willing to submit recommendations and endpoint limited to therapy recommendations. Conclusions: Among test orderers, serum-based proteomic mass spectrometry testing significantly influenced therapy recommendations in NSCLC. Usage patterns should be monitored as use expands.
----------------------------------------------------
[18]
TÍTULO / TITLE: - A meta-analysis of evidences on XPC polymorphisms and lung cancer susceptibility.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Tumour Biol. 2013 Apr;34(2):1205-13. doi: 10.1007/s13277-013-0663-9. Epub 2013 Feb 6.
●● Enlace al texto completo (gratuito o de pago) 1007/s13277-013-0663-9
AUTORES / AUTHORS: - Liu C; Yin Q; Hu J; Li L; Zhang Y; Wang Y
INSTITUCIÓN / INSTITUTION: - Department of Oncology, Changhai Hospital, The Second Military Medical University, 168 Changhai Road, Shanghai, 200433, People’s Republic of China, chuanliu2005@163.com.
RESUMEN / SUMMARY: - Published data regarding the association between the XPC polymorphisms and lung cancer susceptibility remained controversial. This meta-analysis was performed to draw a precise estimation of the relationship. We systematically searched PubMed, Embase, Elsevier, and Web of Science with a time limit of September 10, 2012. Summary odds ratios (ORs) with 95 % CIs were used to assess the strength of association between these polymorphisms and lung cancer susceptibility using random-effects model. This meta-analysis including 13 case-control studies evaluated the associations between three commonly XPC polymorphisms (Lys939Gln, Ala499Val, and PAT(-/+)) and lung cancer susceptibility. No significant associations were found between the three XPC polymorphisms and lung cancer susceptibility (for Lys939Gln polymorphism: CC vs AA, OR = 1.191, p = 0.033; AC vs AA, OR = 0.992, p = 0.762, the dominant model, OR = 1.028, p = 0.521; the recessive model, OR = 1.205, p = 0.022). For Ala499Val polymorphism: TT vs CC, OR = 1.195, p = 0.071; TC vs CC, OR = 1.146, p = 0.133; the dominant model, OR = 1.161, p = 0.086; the recessive model, OR = 1.123, p = 0.156. For PAT(-/+) polymorphism: +/+ vs -/-, OR = 1.094, p = 0.539; +/- vs -/-, OR = 0.925, p = 0.313; the dominant model, OR = 0.969, p = 0.725; the recessive model, OR = 1.135, p = 0.290. p = 0.004 for Bonferroni testing). Significant associations were also not found in the subgroup analysis for the three XPC polymorphisms. This meta-analysis suggested that the three XPC polymorphisms might not be risk factors for developing lung cancer.
----------------------------------------------------
[19]
TÍTULO / TITLE: - The role of videomediastinoscopy in staging of non-small cell lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Coll Antropol. 2012 Dec;36(4):1441-4.
AUTORES / AUTHORS: - Bacic I; Skarica R; Sulen N; Zadro Z; Lisica-Sikic N; Karlo R; Petani B
INSTITUCIÓN / INSTITUTION: - Zadar General Hospital, Department of Surgery, Zadar, Croatia. ivan.bacic21@zd.t-com.hr
RESUMEN / SUMMARY: - Lung cancer is the most frequent malignant disease and the leading cause of death from malignant diseases in the world and its incidence is increasing. At the time when diagnosis is established most patients have advanced disease and are not candidates for radical surgical treatment. Patients without distant metastases are subjected to various diagnostic methods to detect metastases in mediastinal lymph nodes that make up the path of lymph drainage from the lungs. The most reliable invasive diagnostic procedures for detecting metastases in mediastinal lymph nodes are videomediastinoscopy and endobronchial ultrasound with transtracheal puncture. In the absence of mediastinal lymph node metastases surgery is the treatment of choice. If mediastinal lymph nodes are positive for metastases multimodal treatment is implemented. At the Department of Thoracic Surgery, Zadar General Hospital, videomediastinoscopy for the staging of primary non-small cell lung cancer has been performed routinely since September 2009.
----------------------------------------------------
[20]
TÍTULO / TITLE: - Cox-2 in non-small cell lung cancer: A meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Clin Chim Acta. 2013 Apr 18;419:26-32. doi: 10.1016/j.cca.2013.01.012. Epub 2013 Feb 4.
●● Enlace al texto completo (gratuito o de pago) 1016/j.cca.2013.01.012
AUTORES / AUTHORS: - Jiang H; Wang J; Zhao W
INSTITUCIÓN / INSTITUTION: - Department of Geriatric Oncology, the Second Affiliated Hospital, Southeast University, 1-1 Zhongfu Street, Nanjing, Jiangsu 210003, PR China. Electronic address: gfdsa_1234567@sohu.com.
RESUMEN / SUMMARY: - BACKGROUND: We investigated the prognostic value of cyclooxygenase-2 (COX-2) for survival of patients with non-small cell lung cancer (NSCLC). METHODS: We performed a meta-analysis of literature to aggregate the available survival results, using studies published in English until June 2012. Eligible studies dealt with COX-2 protein assessment in NSCLC patients on primary lesions and reported survival data according to COX-2 expression. RESULTS: Nineteen trials, comprising 2651 patients, provided sufficient information for the meta-analysis. Overall combined hazard ratio (HR) was 1.86 (95% CI: 1.58-2.20); it was calculated using a random-effects model, and associates high COX-2 expression with poor survival in all NSCLC patients. Aggregate survival data showed poor survival for patients with adenocarcinoma (ADC), squamous cell cancer (SCC) and Stage I NSCLC with high COX-2 expression, at 2.00 (95% CI: 1.38-2.88), 2.29 (95% CI: 1.58-3.33) and 1.95 (95% CI: 1.31-2.91) respectively. CONCLUSIONS: Our meta-analysis shows that the COX-2 expression status is an independent prognostic factor in NSCLC, and this tendency applies to SCC, ADC and stage I NSCLC.
----------------------------------------------------
[21]
TÍTULO / TITLE: - Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Trials. 2013 Feb 15;14(1):45. doi: 10.1186/1745-6215-14-45.
●● Enlace al texto completo (gratuito o de pago) 1186/1745-6215-14-45
AUTORES / AUTHORS: - Hu L; Liang G; Yuliang W; Bingjing Z; Xiangdong Z; Rufu X
INSTITUCIÓN / INSTITUTION: - Department of Respiratory Diseases, The First Affiliated Hospital of Third Military Medical University, Chongqing, 400038, People’s Republic of China. xiangdongzhou@126.com.
RESUMEN / SUMMARY: - BACKGROUND: Lung cancer is still the leading cause of cancer-related mortality worldwide. Around 80 to 85% of lung cancers are non-small cell lung cancer (NSCLC). Regional lymphatic metastasis is a frequent occurrence in NSCLC, and the extent of lymphatic dissemination significantly determines the prognosis of patients with NSCLC. Hence, identification of alternative treatments for these patients should be considered a priority. Liposomal paclitaxel is a new formulation composed of paclitaxel and liposomes, with favorable pharmacokinetic properties. In particular, it produces dramatically higher drug concentrations in the lymph nodes than occurs with the current formulations of paclitaxel, thus we believe that patients with NSCLC with regional lymphatic metastasis may benefit from this new drug. Cisplatin-based doublet chemotherapy is recommended as the first-line treatment for patients with advanced NSCLC. We have designed a trial to assess whether first-line chemotherapy using liposomal paclitaxel combined with cisplatin (LP regimen) is superior to gemcitabine combined with cisplatin (GP regimen) in efficacy (both short-term and long-term efficacy) and safety (adverse events; AEs). METHOD/DESIGN: This is a prospective, open-label, controlled randomized clinical trial (RCT) to assess the therapeutic effects and safety of liposomal paclitaxel. The study aims to enroll 126 patients, who will be randomly allocated to one of the two treatment groups (LP and GP), with 63 patients in each group. Patients will receive four to six cycles of the assigned chemotherapy, and primary outcome will be assessed every two cycles. Patients will be recommended for surgery if the tumor becomes resectable. All participants will be followed up for at least 12 months. The objective response rate (ORR), changes in regional lymphatic metastasis (including number and size) and TNM (tumor, node, metastasis) staging will be the primary outcome measures. Progression-free survival, objective survival, median survival time, 1-year survival rate, toxicity, and time to disease progression will be the secondary outcome measures. CONCLUSIONS: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for patients with NSCLC with regional lymphatic metastasis. TRIAL REGISTRATION: chictr.org Identifier: ChiCTR-TRC-12602105.
----------------------------------------------------
[22]
TÍTULO / TITLE: - Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Health Technol Assess. 2013 Feb;17(6):1-99. doi: 10.3310/hta17060.
●● Enlace al texto completo (gratuito o de pago) 3310/hta17060
AUTORES / AUTHORS: - Brown T; Pilkington G; Boland A; Oyee J; Tudur Smith C; Dundar Y; Richards E; Yang R; Dickson R
INSTITUCIÓN / INSTITUTION: - Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK.
RESUMEN / SUMMARY: - BACKGROUND: The National Institute for Health and Clinical Excellence has issued guidelines on the treatment of non-small cell lung cancer (NSCLC) and recommends that patients with stage IIIA-IIIB disease who are not amenable to surgery be treated with potentially curative chemoradiation (CTX-RT). This review was conducted as part of a larger systematic review of all first-line chemotherapy (CTX) and CTX-RT treatments for patients with locally advanced or metastatic NSCLC. However, it was considered that patients with potentially curable disease (e.g. stage IIIA) are different from those with advanced disease, who are suitable for palliative treatment only, and therefore the results should be reported separately. OBJECTIVE: To evaluate the clinical effectiveness of first-line CTX in addition to radiotherapy (RT) (CTX-RT vs CTX-RT) for adult patients with locally advanced NSCLC who are suitable for potentially curative treatment. DATA SOURCES: Three electronic databases (MEDLINE, EMBASE and The Cochrane Library) were searched from January 1990 to September 2010. REVIEW METHODS: Inclusion criteria comprised adult patients with locally advanced NSCLC, trials that compared any first-line CTX-RT therapy (induction, sequential, concurrent and consolidation) and outcomes of overall survival (OS) and/or progression-free survival (PFS). The results of clinical data extraction and quality assessment were summarised in tables and with narrative description. Direct meta-analyses using OS data were undertaken where possible: sequential CTX-RT compared with concurrent CTX-RT; sequential CTX-RT compared with concurrent/consolidation CTX-RT; and sequential CTX-RT compared with concurrent CTX-RT with or without consolidation. There were not sufficient data to perform meta-analysis on PFS. RESULTS: Of the 240 potentially relevant studies that were published post 2000, 19 met the inclusion criteria and compared CTX-RT with CTX-RT. The results from the OS meta-analysis comparing sequential CTX-RT with concurrent CTX-RT appear to show an OS advantage for concurrent CTX-RT arms over sequential arms; this result is not statistically significant [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.50 to 1.25)]. The results from the OS meta-analysis comparing sequential CTX-RT with concurrent/consolidation CTX-RT appear to show a statistically significant OS advantage for concurrent/consolidation CTX-RT treatment over sequential treatment (HR 0.68; 95% CI 0.55 to 0.83). The results from the OS meta-analysis comparing sequential CTX-RT with concurrent CTX-RT with or without consolidation appear to show a statistically significant OS advantage for concurrent CTX-RT with or without consolidation over sequential treatment (HR 0.72; 95% CI 0.61 to 0.84). LIMITATIONS: This report provides a summary and critical appraisal of a comprehensive evidence base of CTX-RT trials; however, it is possible that additional trials have been reported since our last literature search. It is disappointing that the quality of the research in this area does not meet the accepted quality standards regarding trial design and reporting. CONCLUSIONS: This review identified that the research conducted in the area of CTX-RT was generally of poor quality and suffered from a lack of reporting of all important clinical findings, including OS. The 19 trials included in the systematic review were too disparate to form any conclusions as to the effectiveness of individual CTX agents or types of RT. The focus of primary research should be good methodological quality; appropriate allocation of concealment and randomisation, and comprehensive reporting of key outcomes, will enable meaningful synthesis and conclusions to be drawn. FUNDING: The National Institute for Health Research Health Technology Assessment programme.
----------------------------------------------------
[23]
TÍTULO / TITLE: - Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - British Medical J (BMJ). Acceso gratuito al texto completo.
●● Enlace a la Editora de la Revista bmj.com/search.dtl
●● Cita: British Medical J. (BMJ): <> Open. 2013 Mar 13;3(3). pii: e001802. doi: 10.1136/bmjopen-2012-001802. Print 2013.
●● Enlace al texto completo (gratuito o de pago) 1136/bmjopen-2012-001802
AUTORES / AUTHORS: - Laporte S; Squifflet P; Baroux N; Fossella F; Georgoulias V; Pujol JL; Douillard JY; Kudoh S; Pignon JP; Quinaux E; Buyse M
INSTITUCIÓN / INSTITUTION: - Universite Jean Monnet, Saint-Etienne, France.
RESUMEN / SUMMARY: - OBJECTIVES: To investigate whether progression-free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in advanced non-small-cell lung cancer (NSCLC). DESIGN: Meta-analysis of individual patient data from randomised trials. SETTING: Five randomised controlled trials comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC. PARTICIPANTS: 2331 patients with advanced NSCLC. PRIMARY AND SECONDARY OUTCOME MEASURES: Surrogacy of PFS for OS was assessed through the association between these endpoints and between the treatment effects on these endpoints. The surrogate threshold effect was the minimum treatment effect on PFS required to predict a non-zero treatment effect on OS. RESULTS: The median follow-up of patients still alive was 23.4 months. Median OS was 10 months and median PFS was 5.5 months. The treatment effects on PFS and OS were correlated, whether using centres (R²=0.62, 95% CI 0.52 to 0.72) or prognostic strata (R²=0.72, 95% CI 0.60 to 0.84) as units of analysis. The surrogate threshold effect was a PFS hazard ratio (HR) of 0.49 using centres or 0.53 using prognostic strata. CONCLUSIONS: These analyses provide only modest support for considering PFS as an acceptable surrogate for OS in patients with advanced NSCLC. Only treatments that have a major impact on PFS (risk reduction of at least 50%) would be expected to also have a significant effect on OS. Whether these results also apply to targeted therapies is an open question that requires independent evaluation.
----------------------------------------------------
[24]
TÍTULO / TITLE: - Physical activity and the risk of developing lung cancer among smokers: A meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Sci Med Sport. 2013 Mar 22. pii: S1440-2440(13)00047-9. doi: 10.1016/j.jsams.2013.02.015.
●● Enlace al texto completo (gratuito o de pago) 1016/j.jsams.2013.02.015
AUTORES / AUTHORS: - Buffart LM; Singh AS; van Loon EC; Vermeulen HI; Brug J; Chinapaw MJ
INSTITUCIÓN / INSTITUTION: - VU University Medical Center, Department of Epidemiology and Biostatistics, The Netherlands. Electronic address: l.buffart@vumc.nl.
RESUMEN / SUMMARY: - OBJECTIVE: To investigate the relationship between physical activity and lung cancer among smokers and whether this relationship differed according to physical activity intensity, smoking status, and gender. DESIGN: Meta-analysis. METHODS: A computerized bibliographical search was conducted in five databases. Study inclusion criteria were: (i) the study population was not diagnosed with lung cancer at baseline; (ii) the study provided information concerning the effect size of physical activity on the risk of developing lung cancer in smokers; and (iii) the study distinguished different physical activity intensity levels. Two authors independently extracted data and assessed the methodological quality. Pooled rate ratios (RR) were calculated for all data, and for subgroups of physical activity intensity, smoking status, and gender. RESULTS: Pooled RRs of 7 cohort studies showed that physical activity was associated with a reduced risk of lung cancer in smokers (RR=0.82, 95% CI=0.77; 0.87). We did not find clear dose-response relationship regarding exercise or smoking intensity, i.e. high levels of physical activity did not show a higher risk reduction than moderate physical activity levels, and the association between physical activity and risk reduction did not differ between heavy and light smokers. The reduced risk associated with physical activity was greater in women than in men (p=0.03), but this finding was based on only one study that reported data on women. CONCLUSION: Results of this meta-analysis indicate that leisure time physical activity is associated with reduced risk of developing lung cancer among smokers. Future studies should provide insight into a potential dose-response relationship, and should use reliable and valid physical activity measurements.
----------------------------------------------------
[25]
TÍTULO / TITLE: - Epidemiology and clinical characteristics of larynx and hypopharynx carcinoma: a comparative study in the Hainaut and review of the literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Acta Chir Belg. 2012 Nov-Dec;112(6):423-5.
AUTORES / AUTHORS: - Dequanter D; Lothaire P; Zouaoui K; Brohee D
INSTITUCIÓN / INSTITUTION: - Department of Head and Neck Surgery, CHU Charleroi (Vesale), Montigny le Tilleul, Belgium. didier.dequanter@chu-charleroi.be
RESUMEN / SUMMARY: - INTRODUCTION: The epidemiology and clinical picture of laryngeal and hypopharyngeal carcinomas have changed significantly in the past 50 years. The aim of this study was to analyze selected epidemiological and clinical characteristics of laryngeal and hypopharyngeal carcinoma. METHODS: A complete chart review of all patients records was conducted. All the patients who were diagnosed as having laryngeal or hypopharyngeal cancer from January 1, 2004 through December 31, 2009 were included in the study. The demographics of the patient population, the disease profile were analyzed. RESULTS: 138 patients with laryngeal or hypopharyngeal disease were treated. 76 patients presented a laryngeal cancer. Disease characteristics indicated that most cases of supraglottic cancer were in a locally advanced stage (84.4%), whereas most patients with glottis cancer were diagnosed with early stage (63.3%). A hypopharyngeal cancer was diagnosed in 62 cases. A significant increasing trend in hypopharyngeal cancer has been seen in males. The majority of the patients was alcohol consumers and had a histology showing squamous cell carcinoma. There were 33 females and 105 males whose ages ranged at presentation from 47 to 86 years. Of the 138 patients treated, 24 and 47 patients were respectively T3 and T4 and 37 patients were N1, 37 patients N2 and 10 patients N3 (Table I). Most patients had stage IV disease (65/138). Majority of cases presented with local advanced stage. Of the 138 patients treated, 24 and 47 patients were respectively T3 and T4. The highest rate of local advanced stage was observed in patients with pyriform sinus carcinomas (81%); the lowest rate was observed for glottis tumors (41.8%). Regional lymph node metastases were diagnosed in 61% of the analyzed cases. 37 patients were N1, 37 patients N2 and 10 patients N3. The highest rate (82.2%) of regional lymph node metastases were observed in cases of pyriform sinus carcinomas, and the lowest (31.7%) in glottis carcinomas. Most patients had stage IV disease (65/138). 49 patients received radiotherapy; 48 patients were treated by surgery followed by (chemo)radiotherapy. 41 patients were treated initially by concomitant chemoradiotherapy. CONCLUSION: A tendency for increasingly younger patients to develop larynx and hypopharynx carcinomas was observed. Most patients had stage IV disease but no trend for a percentage increase in locally advanced tumors was observed. A significant increasing trend in hypopharyngeal cancer has been seen in males.
----------------------------------------------------
[26]
TÍTULO / TITLE: - Cancer screening in the United States, 2013: A review of current american cancer society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - CA Cancer J Clin. 2013 Mar;63(2):87-105. doi: 10.3322/caac.21174. Epub 2013 Feb 1.
●● Enlace al texto completo (gratuito o de pago) 3322/caac.21174
AUTORES / AUTHORS: - Smith RA; Brooks D; Cokkinides V; Saslow D; Brawley OW
INSTITUCIÓN / INSTITUTION: - Senior Director, Cancer Control Science Department, American Cancer Society, Atlanta, GA. robert.smith@cancer.org.
RESUMEN / SUMMARY: - Answer questions and earn CME/CNE Each year the American Cancer Society (ACS) publishes a summary of its recommendations for early cancer detection, a report on data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, current ACS cancer screening guidelines are summarized, as are updated guidelines on cervical cancer screening and lung cancer screening with low-dose helical computed tomography. The latest data on the use of cancer screening from the National Health Interview Survey also are described, as are several issues related to screening coverage under the Patient Protection and Affordable Care Act of 2010. CA Cancer J Clin 2013. Esta es una cita bibliográfica que va por delante de la publicación en papel. La fecha indicada en la cita provista, NO corresponde con la fecha o la cita bibliográfica de la publicación en papel. La cita bibliográfica definitiva (con el volumen y su paginación) saldrá en 1 ó 2 meses a partir de la fecha de la emisión electrónica-online. *** This is a bibliographic record ahead of the paper publication. The given date in the bibliographic record does not correspond to the date or the bibliographic citation on the paper publication. The publisher will provide the final bibliographic citation (with the volume, and pagination) within 1 or 2 months from the date the record was published online. © 2013 American Cancer Society.
----------------------------------------------------
[27]
TÍTULO / TITLE: - Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Syst Rev. 2013 Feb 4;2(1):10. doi: 10.1186/2046-4053-2-10.
●● Enlace al texto completo (gratuito o de pago) 1186/2046-4053-2-10
AUTORES / AUTHORS: - Wao H; Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
INSTITUCIÓN / INSTITUTION: - Center for Evidence Based Medicine and Outcomes Research, Department of Internal Medicine, Morsani College of Medicine, University of South Florida Clinical and Translational Science Institute, 3515 East Fletcher Avenue, MDT 1202, Tampa, FL, 33612, USA. akumar1@health.usf.edu.
RESUMEN / SUMMARY: - BACKGROUND: Lung cancer is considered a terminal illness with a five-year survival rate of about 16%. Informed decision-making related to the management of a disease requires accurate prognosis of the disease with or without treatment. Despite the significance of disease prognosis in clinical decision-making, systematic assessment of prognosis in patients with lung cancer without treatment has not been performed. We conducted a systematic review and meta-analysis of the natural history of patients with confirmed diagnosis of lung cancer without active treatment, to provide evidence-based recommendations for practitioners on management decisions related to the disease. Specifically, we estimated overall survival when no anticancer therapy is provided. METHODS: Relevant studies were identified by search of electronic databases and abstract proceedings, review of bibliographies of included articles, and contacting experts in the field. All prospective or retrospective studies assessing prognosis of lung cancer patients without treatment were eligible for inclusion. Data on mortality was extracted from all included studies. Pooled proportion of mortality was calculated as a back-transform of the weighted mean of the transformed proportions using the random-effects model. To perform meta-analysis of median survival, published methods were used to pool the estimates as mean and standard error under the random-effects model. Methodological quality of the studies was examined. RESULTS: Seven cohort studies (4,418 patients) and 15 randomized controlled trials (1,031 patients) were included in the meta-analysis. All studies assessed mortality without treatment in patients with non-small cell lung cancer (NSCLC). The pooled proportion of mortality without treatment in cohort studies was 0.97 (95% CI: 0.96 to 0.99) and 0.96 in randomized controlled trials (95% CI: 0.94 to 0.98) over median study periods of eight and three years, respectively. When data from cohort and randomized controlled trials were combined, the pooled proportion of mortality was 0.97 (95% CI: 0.96 to 0.98). Test of interaction showed a statistically non-significant difference between subgroups of cohort and randomized controlled trials. The pooled mean survival for patients without anticancer treatment in cohort studies was 11.94 months (95% CI: 10.07 to 13.8) and 5.03 months (95% CI: 4.17 to 5.89) in RCTs. For the combined data (cohort studies and RCTs), the pooled mean survival was 7.15 months (95% CI: 5.87 to 8.42), with a statistically significant difference between the two designs. Overall, the studies were of moderate methodological quality. CONCLUSION: Systematic evaluation of evidence on prognosis of NSCLC without treatment shows that mortality is very high. Untreated lung cancer patients live on average for 7.15 months. Although limited by study design, these findings provide the basis for future trials to determine optimal expected improvement in mortality with innovative treatments.
----------------------------------------------------
[28]
TÍTULO / TITLE: - Mesothelioma associated with use of drywall joint compound: a case series and review of literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Int J Occup Environ Health. 2012 Oct-Dec;18(4):337-43. doi: 10.1179/2049396712Y.0000000009.
●● Enlace al texto completo (gratuito o de pago) 1179/2049396712Y.0000000009
AUTORES / AUTHORS: - Dahlgren J; Peckham T
INSTITUCIÓN / INSTITUTION: - James Dahlgren Medical, Santa Monica, CA, USA. dahlgren@envirotoxicology.com
RESUMEN / SUMMARY: - BACKGROUND: Drywall joint compound contained asbestos fibers, primarily chrysotile, in the 1950s through the 1970s. Workers in a variety of construction trades and homeowners were exposed to respirable asbestos from the use of these products, including during handling, mixing, sanding, and sweeping. Disturbance of in-place asbesto-containing joint compound continues to be a potential source of exposure during demolition or repair of wallboard. Studies from the 1970s and 1980s report air fiber measurements above current and historic regulatory limits during intended usage, and typical asbestos-related disease in drywall construction workers. OBJECTIVES: We present three cases of mesothelioma in which the only known exposure to asbestos was from joint compound and review the literature on exposure circumstances, dose and fiber types. CONCLUSIONS: Physicians treating mesothelioma patients should obtain a history of exposure to these products during work or home remodeling.
----------------------------------------------------
[29]
TÍTULO / TITLE: - The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - PLoS One. 2013;8(1):e54970. doi: 10.1371/journal.pone.0054970. Epub 2013 Jan 25.
●● Enlace al texto completo (gratuito o de pago) 1371/journal.pone.0054970
AUTORES / AUTHORS: - Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
INSTITUCIÓN / INSTITUTION: - Department of Thoracic Surgery, Jiangsu Cancer Hospital, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
RESUMEN / SUMMARY: - BACKGROUND: The prognostic significance of p16 promoter hypermethylation in patients with non-small cell lung cancer (NSCLC) is still controversial. This analysis presents pooled estimates of the association to better elucidate whether p16 methylation has a prognostic role in NSCLC. METHODS: Relevant studies were identified by searching PubMed, Embase and Web of Science databases until June 2012. The association of p16 methylation with both overall survival (OS) and disease-free survival (DFS) was preformed. Studies were pooled and summary hazard ratios (HR) were calculated. Subgroup analyses, sensitivity analysis and publication bias were also conducted. RESULTS: A total of 18 studies containing 2432 patients met the inclusion criteria and had sufficient survival data for quantitative aggregation. The results showed that p16 methylation was an indicator of poor prognosis in NSCLC. The HR was 1.36 (95% CI: 1.08-1.73, I(2) = 56.7%) and 1.68 (95% CI: 1.12-2.52, I(2) = 38.7%) for OS and DFS, respectively. Subgroup analyses were carried out. The HRs of fresh and paraffin tissue were 1.50 (95% CI: 1.11-2.01) and 1.10 (95% CI: 0.77-1.57). The pooled HR was 1.40 (95% CI: 1.02-1.92) for methylation-specific PCR (MSP) and 1.26 (95% CI: 0.87-1.82) for quantitative MSP (Q-MSP). The combined HR of the 16 studies reporting NSCLC as a whole indicated that patients with p16 hypermethylation had poor prognosis. No significant association was found when adenocarcinoma subtype pooled. When seven studies on DFS were aggregated, the HR was 1.68 (95% CI: 1.12-2.52) without significant heterogeneity. Moreover, no obvious publication bias was detected on both OS and DFS. CONCLUSION: The meta-analysis findings support the hypothesis that p16 methylation is associated with OS and DFS in NSCLC patients. Large well-designed prospective studies are now needed to confirm the clinical utility of p16 methylation as an independent prognostic marker.
----------------------------------------------------
[30]
TÍTULO / TITLE: - Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Thorac Dis. 2013 Feb;5(1):40-7. doi: 10.3978/j.issn.2072-1439.2013.01.02.
●● Enlace al texto completo (gratuito o de pago) 3978/j.issn.2072-1439.2013.01.02
AUTORES / AUTHORS: - Zhan P; Qian Q; Yu LK
INSTITUCIÓN / INSTITUTION: - First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, China.
RESUMEN / SUMMARY: - BACKGROUND: Cyclooxygenase-2 (COX-2) has been implicated in tumorigenesis and metastasis, and it presumably mediates the proliferation of endothelial cells and promotes vascular permeability. However, the prognostic value of COX-2 overexpression in patients with non-small cell lung cancer (NSCLC) remains controversial. METHODS: A systematic review of eligible studies with meta-analysis was performed to quantitatively review the correlation of COX-2 overexpression with survival in patients with NSCLC. RESULTS: We conducted a final analysis of 1,892 patients from 16 studies. The studies were categorized by histology, disease stage, patient race and laboratory techniques used. Combined hazard ratios (HR) suggested that COX-2 overexpression was not associated with a significant impact on survival, the HR (95% CI) was 0.90 (95% CI: 0.76-1.04) overall, 0.99 (0.71-1.26) in Asian patients, 0.87 (0.71-1.03) in non-Asian patients, 0.63 (0.33-0.93) in adenocarcinoma, 1.42 (1.02-1.81) in stage I NSCLC, 0.83 (0.72-1.08) in NSCLC by IHC, 3.28 (1.48-5.13) in NSCLC by RT-PCR. CONCLUSIONS: COX-2 overexpression seems to have no significant impact on survival of NSCLC patients. However, the statistically significant was found in stage I NSCLC, suggesting that COX-2 expression could be useful at early stages to distinguish those with a worse prognosis.
----------------------------------------------------
[31]
TÍTULO / TITLE: - Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - PLoS One. 2013;8(1):e55128. doi: 10.1371/journal.pone.0055128. Epub 2013 Jan 30.
●● Enlace al texto completo (gratuito o de pago) 1371/journal.pone.0055128
AUTORES / AUTHORS: - Liu HB; Wu Y; Lv TF; Yao YW; Xiao YY; Yuan DM; Song Y
INSTITUCIÓN / INSTITUTION: - Respiratory Department, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
RESUMEN / SUMMARY: - BACKGROUND: The aim of this study was to assess the role of skin rash in predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the prognosis of patients with non-small cell lung cancer (NSCLC). METHOD: We systematically searched for eligible articles investigating the association between rash and the efficacy of EGFR-TKIs and the prognosis of patients with NSCLC. The summary risk ratio (RR) and hazard ratio (HR) were calculated using meta-analysis. RESULTS: We identified 33 eligible trials involving 6,798 patients. We used two different standards to group the patients [standard 1: rash vs. no rash, standard 2: rash (>/= stage 2) vs. rash (stage 0, 1)]. For standard 1, the objective response rate (ORR) and disease control rate (DCR) of the rash group were significantly higher than the no rash group [RR = 3.28; 95% CI: 2.41-4.47(corrected RR = 2.225, 95% CI: 1.658-2.986); RR = 1.96, 95% CI: 1.58-2.43]. The same results were observed for standard 2. For standards 1 and 2, the progression-free survival (PFS) (HR = 0.45, 95% CI: 0.37-0.53; HR = 0.57, 95% CI: 0.50-0.65) and overall survival (OS) (HR = 0.40, 95% CI: 0.28-0.52; HR = 0.53, 95% CI: 0.35-0.71) of the rash group were significantly longer than the control group, and the same results were observed in the subgroup analysis. CONCLUSIONS: skin rash after EGFR-TKI treatment may be an efficient clinical marker for predicting the response of patients with NSCLC to EGFR-TKIs. Furthermore, skin rash is also the prognostic factor of patients with NSCLC. Patients with skin rash have a longer PFS and OS.
----------------------------------------------------
[32]
TÍTULO / TITLE: - Different protocols for cryobiopsy versus forceps biopsy in diagnosis of patients with endobronchial tumors.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Pneumologia. 2012 Oct-Dec;61(4):230-3.
AUTORES / AUTHORS: - Jabari H; Sami R; Fakhri M; Kiani A
INSTITUCIÓN / INSTITUTION: - Tracheal Diseases Research Center, National Research Institute of Tuberlosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
RESUMEN / SUMMARY: - INTRODUCTION: Forceps biopsy is the standard procedure to obtain specimens in endobronchial lesions. New studies have proposed flexible cryoprobe as an accepted alternative method for this technique. Although diagnostic use of the cryobiopsy is confirmed in few studies, there is paucity of data with regard to an optimum protocol for this method since one of the main considerations in cryobiopsy is the freezing time. OBJECTIVES: To evaluate diagnostic yield and safety of endobronchial biopsies using the flexible cryoprobe. Moreover, different freezing times were assessed to propose an optimized protocol for this diagnostic modality. PATIENTS AND METHODS: For each patient with a confirmed intrabronchial lesion, diagnostic o value of forceps biopsy, cryobiopsy in three seconds, cryobiopsy in five seconds and combined results of cryobiopsy in both timings were recorded. RESULTS: A total of 60 patients (39 males and 21 females; Mean age 56.7 +/- 13.3) were included. Specimens that were obtained by cryobiopsy in five seconds were significantly larger than those of forceps biopsy and cryobiopsy in three seconds (p < 0.001). We showed that the achieved diagnostic yields for all three methods were not statistically different (p > 0.05). Simultaneous usage of samples produced in both cryobiopsies can significantly improve the diagnostic yield (p = 0.02). Statistical analysis showed that there were no significant differences in case of bleeding frequency among the three sampling methods. CONCLUSIONS: This study confirmed safety and feasibility of cryobiopsy. Additionally, combination of sampling with two different cold induction timings would significantly increase sensitivity of this emerging technique.
----------------------------------------------------
[33]
TÍTULO / TITLE: - Prognostic significance of beta-catenin expression in patients with non-small cell lung cancer: A meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Biosci Trends. 2013 Feb;7(1):42-9.
AUTORES / AUTHORS: - Mei XD; Su H; Song J; Dong L
INSTITUCIÓN / INSTITUTION: - Department of Pulmonary Medicine, Qilu Hospital, Shandong University, Ji’nan, Shandong, China.
RESUMEN / SUMMARY: - beta-Catenin has been reported to play a crucial role in the invasion and metastasis of lung cancer. However, the value of beta-catenin as a prognostic factor for non-small cell lung cancer (NSCLC) remains controversial. The present study systematically reviewed the evidence of predicting significance of beta-catenin expression in NSCLC patients with meta-analysis. Twelve literatures were included by searching PubMed, Cochrane library, and EMBASE databases. Separate hazard ratio estimates and a 95% confidence interval (CI) for the prognostic value of beta-catenin in NSCLC were extracted and merged from the included literatures. The summary hazard ratios were 1.91 (95% CI 1.60-2.28), indicating a worse overall survival for NSCLC patients with reduced beta-catenin expression. There was no significant heterogeneity among the studies (X(2) = 12.41, p = 0.413, I(2) = 3.3%). Publication bias was not statistically significant. Sensitivity analysis showed that omission of any single study had little effect on the combined risk estimates. This meta-study revealed that decreased beta-catenin expression denoted a poor prognosis in NSCLC patients.
----------------------------------------------------
[34]
TÍTULO / TITLE: - Managing breathlessness in patients with lung cancer.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Nurs Stand. 2012 Nov 28-Dec 4;27(13):44-9.
AUTORES / AUTHORS: - Cairns L
INSTITUCIÓN / INSTITUTION: - Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne. lindsay.cairns@nuth.nhs.uk
RESUMEN / SUMMARY: - Breathlessness is one of the most common and difficult symptoms to manage in advanced cancer. Despite the development of non-pharmacological interventions and a shift away from a medical approach to its management, symptom control remains suboptimal. Practitioners need education and support to deliver the best possible care for patients experiencing breathlessness. This article provides an overview of the interventions available to improve quality of life for these patients and explores the need for greater implementation of non-pharmacological interventions.
----------------------------------------------------
[35]
TÍTULO / TITLE: - Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - PLoS One. 2013;8(2):e55637. doi: 10.1371/journal.pone.0055637. Epub 2013 Feb 8.
●● Enlace al texto completo (gratuito o de pago) 1371/journal.pone.0055637
AUTORES / AUTHORS: - Qi WX; Wang Q; Jiang YL; Sun YJ; Tang LN; He AN; Min DL; Lin F; Shen Z; Yao Y
INSTITUCIÓN / INSTITUTION: - Department of Oncology, the Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai, China.
RESUMEN / SUMMARY: - BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC. METHODS: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and grade 3 or 4 adverse event (AEs). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. RESULTS: Eight eligible trials involved 2417 patients were ultimately identified. The intention to treatment (ITT) analysis demonstrated that combining targeted therapy significantly improved OS (HR 0.90, 95% CI: 0.82-0.99, p = 0.024), PFS (HR 0.83, 95% CI: 0.72-0.97, p = 0.018), and ORR (OR 1.35, 95% CI 1.01-1.80, P = 0.04). Sub-group analysis based on phases of trials, EGFR-status and KRAS status also showed that there was a tendency to improve PFS and OS in combining targeted therapy, except that PFS for patients with EGFR-mutation or wild type KRAS favored erlotinib monotherapy. Additionally, more incidence of grade 3 or 4 rash, fatigue and hypertension were observed in combining targeted therapy. CONCLUSIONS: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. More studies are still needed to identify patients who will most likely benefit from the appropriate combining targeted therapy.
----------------------------------------------------
[36]
TÍTULO / TITLE: - Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - BMC Cancer. 2013 Mar 27;13(1):158.
●● Enlace al texto completo (gratuito o de pago) 1186/1471-2407-13-158
AUTORES / AUTHORS: - Jafri SH; Shi R; Mills G
RESUMEN / SUMMARY: - BACKGROUND: Systemic inflammation has been linked with cancer development, cancer cachexia and poor outcome. Advanced lung cancer inflammation index (ALI) was developed to assess degree of systemic inflammation at the time of diagnosis in metastatic non-small cell lung (NSCLC) cancer patients. METHODS: In a single institution retrospective review 173 patients with metastatic NSCLC diagnosed between Jan 1 2000 and June 30 2011 were included. ALI was calculated as (BMI x Alb / NLR) where BMI = body mass index, Alb = serum albumin, NLR (neutrophil lymphocyte ratio, a marker of systemic inflammation). Patients were divided into low inflammation (ALI >= 18) and high inflammation (ALI < 18) groups. Kaplan-Meier method was used to estimate progression free survival and overall survival. Log-rank test were used to compare the survivals among various factors. Multivariate Cox regression was used to perform survival analysis in order to estimate the hazards ratio for various factors. RESULTS: Among 173 patients median age was 57 years, 67% were male, 52% had adenocarcinoma. Patients with an ALI score of < 18 suggesting high systemic inflammation were significantly more likely to have more than 2 sites of metastatic disease, have poor performance status and less likely to receive any chemotherapy. Their median progression free survival and overall survival was 2.4 months and 3.4 months as opposed to 5.1 months and 8.3 months in patients with ALI >18 (P < 0.001). On multi-variate analysis ALI score of <18(1.42, 95% CI 1.003-2.01) remained significantly associated with worse outcome. CONCLUSION: ALI (<18) at diagnosis is an independent marker of poor outcome in patients with advanced NSCLC.
----------------------------------------------------
[37]
TÍTULO / TITLE: - Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - PLoS Med. 2013 Feb;10(2):e1001376. doi: 10.1371/journal.pmed.1001376. Epub 2013 Feb 5.
●● Enlace al texto completo (gratuito o de pago) 1371/journal.pmed.1001376
AUTORES / AUTHORS: - Forrest LF; Adams J; Wareham H; Rubin G; White M
INSTITUCIÓN / INSTITUTION: - Fuse, UKCRC Centre for Translational Research in Public Health, Institute of Health & Society, Newcastle University, Newcastle upon Tyne, United Kingdom. Lynne.Forrest1@ncl.ac.uk
RESUMEN / SUMMARY: - BACKGROUND: Intervention-generated inequalities are unintended variations in outcome that result from the organisation and delivery of health interventions. Socioeconomic inequalities in treatment may occur for some common cancers. Although the incidence and outcome of lung cancer varies with socioeconomic position (SEP), it is not known whether socioeconomic inequalities in treatment occur and how these might affect mortality. We conducted a systematic review and meta-analysis of existing research on socioeconomic inequalities in receipt of treatment for lung cancer. METHODS AND FINDINGS: MEDLINE, EMBASE, and Scopus were searched up to September 2012 for cohort studies of participants with a primary diagnosis of lung cancer (ICD10 C33 or C34), where the outcome was receipt of treatment (rates or odds of receiving treatment) and where the outcome was reported by a measure of SEP. Forty-six papers met the inclusion criteria, and 23 of these papers were included in meta-analysis. Socioeconomic inequalities in receipt of lung cancer treatment were observed. Lower SEP was associated with a reduced likelihood of receiving any treatment (odds ratio [OR] = 0.79 [95% CI 0.73 to 0.86], p<0.001), surgery (OR = 0.68 [CI 0.63 to 0.75], p<0.001) and chemotherapy (OR = 0.82 [95% CI 0.72 to 0.93], p = 0.003), but not radiotherapy (OR = 0.99 [95% CI 0.86 to 1.14], p = 0.89), for lung cancer. The association remained when stage was taken into account for receipt of surgery, and was found in both universal and non-universal health care systems. CONCLUSIONS: Patients with lung cancer living in more socioeconomically deprived circumstances are less likely to receive any type of treatment, surgery, and chemotherapy. These inequalities cannot be accounted for by socioeconomic differences in stage at presentation or by differences in health care system. Further investigation is required to determine the patient, tumour, clinician, and system factors that may contribute to socioeconomic inequalities in receipt of lung cancer treatment.
----------------------------------------------------
[38]
TÍTULO / TITLE: - Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Target Oncol. 2013 Mar 21.
●● Enlace al texto completo (gratuito o de pago) 1007/s11523-013-0272-y
AUTORES / AUTHORS: - Pan G; Ke S; Zhao J
INSTITUCIÓN / INSTITUTION: - Department of Thoracic and Cardiovascular Surgery, Zhongnan Hospital, Wuhan University, 169 Donghu Road, Wuchang, Wuhan, Hubei, 430071, People’s Republic of China.
RESUMEN / SUMMARY: - In patients with advanced non-small cell lung cancer (NSCLC), the benefit-to-risk ratio of doublet-targeted agents versus single agent is not clear. A systematic review and quantitative meta-analysis were, therefore, undertaken to evaluate the available evidence from randomized trials. This study aims to evaluate the efficacy and safety of erlotinib versus doublets (erlotinib plus another targeted agent) in advanced NSCLC and, if adequate data are available, to investigate whether or not predefined patient groups benefit more or less from doublet-targeted therapy based on erlotinib. Medline, Embase, and the Cochrane Central Register of Controlled Trials were searched. Randomized controlled clinical trials were conducted in which any erlotinib was compared with doublets based on erlotinib in patients with NSCLC who had failed to respond to any previous chemotherapy regimen. Two review authors independently selected studies for inclusion in the review and extracted data. A systematic review and meta-analysis based on aggregate data extracted from trial publications were carried out to assess the effectiveness of doublets (erlotinib plus another targeted drug) in NSCLC treatment. The efficacy outcomes were objective response rate (ORR), complete response plus partial response; disease control rate (DCR), complete response plus partial response and stable disease; and 1-year overall survival (OS). The adverse effects (AEs) were also considered. This involved identifying eligible randomized controlled trials (RCTs) and extracting aggregate data from the reports of these RCTs. Hazard ratios were calculated from published summary statistics and then combined to give pooled estimates of treatment efficacy. This meta-analysis comprised five studies including 2,100 patients (mean age 63; 1,224 men and 876 women; 118 stage IIIB and 1,180 stage IV; 441 squamous cell cancers, 1,287 adenocarcinomas, and 372 other pathological types). Doublets regimen significantly improved ORR [hazard ratio (HR) 1.49, 1.13-1.98, p < 0.05] and DCR (HR 1.25, 1.12-1.39, p < 0.05) compared with single erlotinib, but 1-year OS was not significantly improved for doublets [HR 1.06; 95 % confidence interval (CI), 0.95-1.18]. All-grade rash, anemia, diarrhea, anorexia, and fatigue were not significantly different between doublet and erlotinib groups (HR 1.25, 0.99-1.58; 0.98, 0.78-1.24; 1.43, 0.97-2.11; 1.18, 0.84-1.65; and 1.23, 0.86-1.77, respectively). The total grade of >/=3 AEs was also not significantly different (HR 1.40, 95 % CI 0.97-2.01). Compared with single-agent erlotinib, doublets (erlotinib plus another targeted agent) significantly improve ORR and DCR, but not OS, and induce no significance of more frequent and serious AEs. The benefit-to-risk ratio of doublets in advanced NSCLC may be more favorable than that of single-agent. The results of this systematic review suggest that patients with advanced NSCLC might benefit from doublet-targeted therapy based on erlotinib compared to erlotinib alone. However, an individual patient data systematic review and meta-analysis are needed to give us a more reliable assessment of the size of benefits and to explore whether doublet therapy may be more or less effective for particular types of patients.
----------------------------------------------------
[39]
TÍTULO / TITLE: - The Efficacy of Chinese Herbal Medicine as an Adjunctive Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - PLoS One. 2013;8(2):e57604. doi: 10.1371/journal.pone.0057604. Epub 2013 Feb 28.
●● Enlace al texto completo (gratuito o de pago) 1371/journal.pone.0057604
AUTORES / AUTHORS: - Li SG; Chen HY; Ou-Yang CS; Wang XX; Yang ZJ; Tong Y; Cho WC
INSTITUCIÓN / INSTITUTION: - Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, China ; Department of Oncology and Hematology, Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen, Guangdong Province, China.
RESUMEN / SUMMARY: - Many published studies reflect the growing application of complementary and alternative medicine, particularly Chinese herbal medicine (CHM) use in combination with conventional cancer therapy for advanced non-small cell lung cancer (NSCLC), but its efficacy remains largely unexplored. The purpose of this study is to evaluate the efficacy of CHM combined with conventional chemotherapy (CT) in the treatment of advanced NSCLC. Publications in 11 electronic databases were extensively searched, and 24 trials were included for analysis. A sum of 2,109 patients was enrolled in these studies, at which 1,064 patients participated in CT combined CHM and 1,039 in CT (six patients dropped out and were not reported the group enrolled). Compared to using CT alone, CHM combined with CT significantly increase one-year survival rate (RR = 1.36, 95% CI = 1.15-1.60, p = 0.0003). Besides, the combined therapy significantly increased immediate tumor response (RR = 1.36, 95% CI = 1.19-1.56, p<1.0E-5) and improved Karnofsky performance score (KPS) (RR = 2.90, 95% CI = 1.62-5.18, p = 0.0003). Combined therapy remarkably reduced the nausea and vomiting at toxicity grade of III-IV (RR = 0.24, 95% CI = 0.12-0.50, p = 0.0001) and prevented the decline of hemoglobin and platelet in patients under CT at toxicity grade of I-IV (RR = 0.64, 95% CI = 0.51-0.80, p<0.0001). Moreover, the herbs that are frequently used in NSCLC patients were identified. This systematic review suggests that CHM as an adjuvant therapy can reduce CT toxicity, prolong survival rate, enhance immediate tumor response, and improve KPS in advanced NSCLC patients. However, due to the lack of large-scale randomized clinical trials in the included studies, further larger scale trials are needed.
----------------------------------------------------
[40]
TÍTULO / TITLE: - Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Oncol Pharm Pract. 2013 Mar 14.
●● Enlace al texto completo (gratuito o de pago) 1177/1078155212474047
AUTORES / AUTHORS: - Chung C; Christianson M
INSTITUCIÓN / INSTITUTION: - Department of Pharmacy, Kennewick General Hospital, WA, USA.
RESUMEN / SUMMARY: - Appropriate evidence-based roles of prognostic and predictive biomarkers of known therapeutic targets in breast, colorectal, and non-small cell lung cancers in adults are reviewed, with summary of evidence for use and recommendation. Current development in biomarker studies is also discussed. Computerized literature searches of PubMed (National Library of Medicine), the Cochrane Collaboration Library, and commonly accepted US and international guidelines (American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network) were performed from 2001 to 2012. Literature published before 2001 was noted for historical interest but not evaluated. Literature review was focused on available systematic reviews and meta-analyses of published predictive (associated with treatment response and/or efficacy) and prognostic (associated with disease outcome) biomarkers of known therapeutic targets in colorectal, breast, and non-small cell lung cancers. In general, significant health outcomes (e.g. predicted response to therapy, overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations. Four breast cancer biomarkers were evaluated, two of which (2D6 genotyping, Oncotype Dx) were considered emerging with insufficient evidence. Seven colorectal cancer biomarkers were evaluated, five of which (EGFR gene expression, K-ras G13D gene mutation, B-raf V600E gene mutation, dihydropyrimidine dehydrogenase deficiency, and UGT1A1 genotyping) were considered emerging. Seven non-small cell lung cancer biomarkers were evaluated, five of which were emerging (EGFR gene expression, ERCC gene expression, RRM1 gene expression, K-ras gene mutation, and TS gene expression). Of all 18 biomarkers evaluated, the following showed evidence of clinical utility and were recommended for routine use in practice: ER/PR and HER2 for breast cancer; K-ras gene mutation (except G13D gene mutation) for colorectal cancer; mismatch repair deficiency or microsatellite instability for colorectal cancer; and EGFR and EML4-ALK gene mutations for non-small cell lung. Not all recommendations for these biomarkers were uniformly supported by all guidelines.
----------------------------------------------------
[41]
TÍTULO / TITLE: - Statins and the risk of lung cancer: a meta-analysis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - PLoS One. 2013;8(2):e57349. doi: 10.1371/journal.pone.0057349. Epub 2013 Feb 28.
●● Enlace al texto completo (gratuito o de pago) 1371/journal.pone.0057349
AUTORES / AUTHORS: - Tan M; Song X; Zhang G; Peng A; Li X; Li M; Liu Y; Wang C
INSTITUCIÓN / INSTITUTION: - Department of Respiratory Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China.
RESUMEN / SUMMARY: - PURPOSE: Several epidemiologic studies have evaluated the association between statins and lung cancer risk, whereas randomized controlled trials (RCTs) on cardiovascular outcomes provide relevant data as a secondary end point. We conducted a meta-analysis of all relevant studies to examine this association. METHODS: A systematic literature search up to March 2012 was performed in PubMed database. Study-specific risk estimates were pooled using a random-effects model. RESULTS: Nineteen studies (5 RCTs and 14 observational studies) involving 38,013 lung cancer cases contributed to the analysis. They were grouped on the basis of study design, and separate meta-analyses were conducted. There was no evidence of an association between statin use and risk of lung cancer either among RCTs (relative risk [RR] 0.91, 95% confidence interval [CI] 0.76-1.09), among cohort studies (RR 0.94, 95% CI 0.82-1.07), or among case-control studies (RR 0.82, 95% CI 0.57-1.16). Low evidence of publication bias was found. However, statistically significant heterogeneity was found among cohort studies and among case-control studies. After excluding the studies contributing most to the heterogeneity, summary estimates were essentially unchanged. CONCLUSION: The results of our meta-analysis suggest that there is no association between statin use and the risk of lung cancer.
----------------------------------------------------
[42]
TÍTULO / TITLE: - Dermatomyositis as an early manifestation and a significant clinical precursor of lung cancer: report of a rare case and review of the current literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Int J Clin Exp Med. 2013;6(2):105-9. Epub 2013 Jan 26.
AUTORES / AUTHORS: - Nikolaos T; Maria T; Ioannis KD; Georgios L; Nikolaos P; Stamatina D; Christos P; Georgios K; Vasileios B; Anna E
INSTITUCIÓN / INSTITUTION: - Second Department of Medical Oncology, “Saint Savvas” Anticancer Hospital Alexandras Avenue 171, 115 22, Athens, Greece.
RESUMEN / SUMMARY: - Dermatomyositis represents an idiopathic inflammatory connective-tissue disease, characterized by inflammation of the muscles and the skin. There is a high incidence of malignancy in patients with dermatomyositis. The main purpose of the present paper is to describe and underline the clinical significance of dermatomyositis manifestations as a precursor and early clinical signs of small cell lung cancer. A physical examination, laboratory tests, anti-Jo-1 antibody and muscle biopsy were performed. The most important findings were SGOT 284 IU/L, CPK 11083 IU/L, aldolase 76.3 IU/L (normal values <7.6). The patient was treated with chemotherapy and a significant improvement of clinical and laboratory findings were noted. The diagnosis of lung cancer could be correlated with the clinical existence of dermatomyositis. Increased awareness is needed regarding the association of dermatomyositis with malignancies in order to achieve correct and timely diagnosis of the underling cancer.
----------------------------------------------------
[43]
TÍTULO / TITLE: - Functional capacity, physical activity and muscle strength assessment of individuals with non-small cell lung cancer: A systematic review of instruments and their measurement properties.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - BMC Cancer. 2013 Mar 20;13(1):135.
●● Enlace al texto completo (gratuito o de pago) 1186/1471-2407-13-135
AUTORES / AUTHORS: - Granger CL; McDonald CF; Parry SM; Oliveira CC; Denehy L
RESUMEN / SUMMARY: - BACKGROUND: The measurement properties of instruments used to assess functional capacity, physical activity and muscle strength in participants with non-small cell lung cancer (NSCLC) have not been systematically reviewed. METHOD: Objectives: To identify outcome measures used to assess these outcomes in participants with NSCLC; and to evaluate, synthesise and compare the measurement properties of the outcome measures identified. Data Sources: A systematic review of articles using electronic databases MEDLINE (1950--2012), CINAHL (1982--2012), EMBASE (1980--2012), Cochrane Library (2012), Expanded Academic ASAP (1994--2012), Health Collection Informit (1995--2012) and PEDRO (1999--2012). Additional studies were identified by searching personal files and cross referencing. Eligibility Criteria for Study Selection: Search one: studies which assessed functional capacity, physical activity or muscle strength in participants with NSCLC using non-laboratory objective tests were included. Search two: studies which evaluated a measurement property (inter- or intra-rater reliability; measurement error; criterion or construct validity; or responsiveness) in NSCLC for one of the outcome measures identified in search one. Studies published in English from 1980 were eligible. Data Extraction and Methodological Quality Assessment: data collection form was developed and data extracted. Methodological quality of studies was assessed by two independent reviewers using the 4-point COSMIN checklist. RESULTS: Thirteen outcome measures were identified. Thirty-one studies evaluating measurement properties of the outcome measures in participants with NSCLC were included. Functional capacity was assessed using the six- and twelve-minute walk tests; incremental- and endurance-shuttle walk tests; and the stair-climbing test. Criterion validity for three of these measures was established in NSCLC but not the reliability or responsiveness. Physical activity was measured using accelerometers and pedometers. Only the construct validity for accelerometers and pedometers was reported. Muscle strength was measured using hand-held dynamometry, hand-grip dynamometry, manual muscle test, one-repetition maximum and the chair-stand test, however only two studies reported reliability and measurement error and one study reported construct validity. CONCLUSION: Currently there is a gap in the literature regarding the measurement properties of commonly used outcome measures in NSCLC participants, particularly reliability, measurement error and responsiveness. Further research needs to be conducted to determine the most suitable outcome measures for use in trials involving NSCLC participants.
----------------------------------------------------
[44]
TÍTULO / TITLE: - Malignant pleural mesothelioma: factors influencing the prognosis.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - Oncology (Williston Park). 2012 Dec;26(12):1164-75.
AUTORES / AUTHORS: - Mineo TC; Ambrogi V
INSTITUCIÓN / INSTITUTION: - Department of Experimental Medicine and Surgery, Policlinico Tor Vergata University, Rome, Italy. mineo@uniroma2.it
RESUMEN / SUMMARY: - Malignant pleural mesothelioma (MPM) is a highly severe primary tumor of the pleura mainly related to exposure to asbestos fibers. The median survival after symptom onset is less than 12 months. Conventional medical and surgical therapies—either as single lines or combined—are not wholly effective. No universally accepted guidelines have yet been established for patient selection and the use of therapeutic strategies. In addition, retrospective staging systems have proved inadequate at improving therapeutic outcomes. Therapy is currently guided by gross tumor characteristics and patient features; however, these seem less accurate than the biological fingerprint of the tumor. A number of clinical prognostic factors have been considered in large multicenter series and independently validated. A series of novel biomarkers can predict the evolution of the disease. Here we summarize the principal and novel factors that influence prognosis and are thus potentially useful for selecting patients for targeted therapy.
----------------------------------------------------
[45]
TÍTULO / TITLE: - Primary pleural squamous cell carcinoma misdiagnosed as localized mesothelioma: a case report and review of the literature.
RESUMEN / SUMMARY: - Enlace al Resumen / Link to its Summary
REVISTA / JOURNAL: - J Cardiothorac Surg. 2013 Mar 17;8(1):50.
●● Enlace al texto completo (gratuito o de pago) 1186/1749-8090-8-50
AUTORES / AUTHORS: - Yang Y; Chi C; Chen J; Liu Y; Li P; Lin XM
RESUMEN / SUMMARY: - Primary pleural squamous cell carcinoma is very rare, and there is a lack of experience in the diagnosis and treatment of this condition. An asymptomatic 75-year-old man was referred to us after a right pleural nodule was found on computed tomography during a routine health examination. He underwent surgery for his pleural tumor twice over the following 2 years. Histopathological examination eventually led to a diagnosis of primary pleural squamous cell carcinoma.
----------------------------------------------------